TWI737086B - Fermentation method for increasing content of effective components in plants - Google Patents
Fermentation method for increasing content of effective components in plants Download PDFInfo
- Publication number
- TWI737086B TWI737086B TW108146489A TW108146489A TWI737086B TW I737086 B TWI737086 B TW I737086B TW 108146489 A TW108146489 A TW 108146489A TW 108146489 A TW108146489 A TW 108146489A TW I737086 B TWI737086 B TW I737086B
- Authority
- TW
- Taiwan
- Prior art keywords
- plant
- patent application
- scope
- item
- acid bacteria
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 82
- 238000000855 fermentation Methods 0.000 title claims abstract description 47
- 230000004151 fermentation Effects 0.000 title claims abstract description 47
- 230000001965 increasing effect Effects 0.000 title claims abstract description 30
- 241000196324 Embryophyta Species 0.000 claims description 117
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 63
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 38
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 claims description 38
- 241000894006 Bacteria Species 0.000 claims description 35
- 230000000694 effects Effects 0.000 claims description 31
- 244000005700 microbiome Species 0.000 claims description 25
- 102000016942 Elastin Human genes 0.000 claims description 24
- 108010014258 Elastin Proteins 0.000 claims description 24
- 229920002549 elastin Polymers 0.000 claims description 24
- 239000000419 plant extract Substances 0.000 claims description 23
- 244000183331 Nephelium lappaceum Species 0.000 claims description 22
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 22
- 230000001737 promoting effect Effects 0.000 claims description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 19
- 239000000203 mixture Substances 0.000 claims description 16
- 102000016267 Leptin Human genes 0.000 claims description 15
- 108010092277 Leptin Proteins 0.000 claims description 15
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 claims description 15
- 229940039781 leptin Drugs 0.000 claims description 15
- 239000003963 antioxidant agent Substances 0.000 claims description 14
- 235000007861 rambutan Nutrition 0.000 claims description 13
- 230000003078 antioxidant effect Effects 0.000 claims description 12
- 230000002708 enhancing effect Effects 0.000 claims description 12
- 230000035755 proliferation Effects 0.000 claims description 12
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 11
- 239000004310 lactic acid Substances 0.000 claims description 11
- 235000014655 lactic acid Nutrition 0.000 claims description 11
- 230000004130 lipolysis Effects 0.000 claims description 11
- 239000003814 drug Substances 0.000 claims description 10
- 235000013305 food Nutrition 0.000 claims description 10
- 230000028327 secretion Effects 0.000 claims description 10
- 235000015738 Nephelium lappaceum Nutrition 0.000 claims description 9
- 238000000605 extraction Methods 0.000 claims description 8
- 239000008103 glucose Substances 0.000 claims description 8
- 244000283763 Acetobacter aceti Species 0.000 claims description 7
- 235000007847 Acetobacter aceti Nutrition 0.000 claims description 7
- 239000000284 extract Substances 0.000 claims description 6
- 235000013824 polyphenols Nutrition 0.000 claims description 5
- 230000009467 reduction Effects 0.000 claims description 5
- 240000006024 Lactobacillus plantarum Species 0.000 claims description 4
- 235000013965 Lactobacillus plantarum Nutrition 0.000 claims description 4
- 229940072205 lactobacillus plantarum Drugs 0.000 claims description 4
- 239000004615 ingredient Substances 0.000 claims 1
- 125000004402 polyphenol group Chemical group 0.000 claims 1
- 239000000047 product Substances 0.000 description 73
- 210000003491 skin Anatomy 0.000 description 49
- 239000002609 medium Substances 0.000 description 30
- 210000004027 cell Anatomy 0.000 description 21
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 20
- 238000002360 preparation method Methods 0.000 description 20
- 239000000243 solution Substances 0.000 description 18
- 238000012360 testing method Methods 0.000 description 18
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 14
- 239000003795 chemical substances by application Substances 0.000 description 14
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 14
- 235000006708 antioxidants Nutrition 0.000 description 13
- 238000010586 diagram Methods 0.000 description 12
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 11
- 239000002953 phosphate buffered saline Substances 0.000 description 11
- 229960005322 streptomycin Drugs 0.000 description 11
- 230000001678 irradiating effect Effects 0.000 description 10
- 230000001580 bacterial effect Effects 0.000 description 9
- 239000003153 chemical reaction reagent Substances 0.000 description 9
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 8
- 229960005070 ascorbic acid Drugs 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 8
- 230000004069 differentiation Effects 0.000 description 8
- 239000012091 fetal bovine serum Substances 0.000 description 8
- 238000002347 injection Methods 0.000 description 8
- 239000007924 injection Substances 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 235000000069 L-ascorbic acid Nutrition 0.000 description 7
- 239000002211 L-ascorbic acid Substances 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 229930182555 Penicillin Natural products 0.000 description 7
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 7
- 239000000975 dye Substances 0.000 description 7
- 229940049954 penicillin Drugs 0.000 description 7
- 230000001603 reducing effect Effects 0.000 description 7
- 230000037303 wrinkles Effects 0.000 description 7
- 108010005094 Advanced Glycation End Products Proteins 0.000 description 6
- 102000008186 Collagen Human genes 0.000 description 6
- 108010035532 Collagen Proteins 0.000 description 6
- 238000002835 absorbance Methods 0.000 description 6
- 229920001436 collagen Polymers 0.000 description 6
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 6
- 239000012086 standard solution Substances 0.000 description 6
- 210000001789 adipocyte Anatomy 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 210000004271 bone marrow stromal cell Anatomy 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- 230000036252 glycation Effects 0.000 description 5
- 235000011187 glycerol Nutrition 0.000 description 5
- 239000007758 minimum essential medium Substances 0.000 description 5
- 206010033307 Overweight Diseases 0.000 description 4
- 239000001888 Peptone Substances 0.000 description 4
- 108010080698 Peptones Proteins 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 239000007795 chemical reaction product Substances 0.000 description 4
- 230000000052 comparative effect Effects 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 239000003349 gelling agent Substances 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 230000000813 microbial effect Effects 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 230000007935 neutral effect Effects 0.000 description 4
- -1 patch Substances 0.000 description 4
- 235000019319 peptone Nutrition 0.000 description 4
- 150000008442 polyphenolic compounds Chemical group 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 210000000229 preadipocyte Anatomy 0.000 description 4
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 102000004877 Insulin Human genes 0.000 description 3
- 108090001061 Insulin Proteins 0.000 description 3
- 208000008589 Obesity Diseases 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 102000004142 Trypsin Human genes 0.000 description 3
- 108090000631 Trypsin Proteins 0.000 description 3
- 239000006096 absorbing agent Substances 0.000 description 3
- 230000032683 aging Effects 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 239000002738 chelating agent Substances 0.000 description 3
- 238000000354 decomposition reaction Methods 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 239000008121 dextrose Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 235000013399 edible fruits Nutrition 0.000 description 3
- 239000003623 enhancer Substances 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 235000021107 fermented food Nutrition 0.000 description 3
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 229940125396 insulin Drugs 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 235000020824 obesity Nutrition 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 238000013207 serial dilution Methods 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 239000012588 trypsin Substances 0.000 description 3
- APIXJSLKIYYUKG-UHFFFAOYSA-N 3 Isobutyl 1 methylxanthine Chemical compound O=C1N(C)C(=O)N(CC(C)C)C2=C1N=CN2 APIXJSLKIYYUKG-UHFFFAOYSA-N 0.000 description 2
- 244000063299 Bacillus subtilis Species 0.000 description 2
- 235000014469 Bacillus subtilis Nutrition 0.000 description 2
- 241000195940 Bryophyta Species 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- RFSUNEUAIZKAJO-VRPWFDPXSA-N D-Fructose Natural products OC[C@H]1OC(O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-VRPWFDPXSA-N 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- 229910021578 Iron(III) chloride Inorganic materials 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- 238000000692 Student's t-test Methods 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 235000013405 beer Nutrition 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000012888 bovine serum Substances 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 2
- 235000005487 catechin Nutrition 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000003246 corticosteroid Substances 0.000 description 2
- 229960001334 corticosteroids Drugs 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 210000004207 dermis Anatomy 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 2
- 229960003957 dexamethasone Drugs 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 239000006196 drop Substances 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- 239000007927 intramuscular injection Substances 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 description 2
- 239000000865 liniment Substances 0.000 description 2
- 229940040145 liniment Drugs 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 235000011929 mousse Nutrition 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 206010033675 panniculitis Diseases 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- 235000019271 petrolatum Nutrition 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000003380 propellant Substances 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 210000001626 skin fibroblast Anatomy 0.000 description 2
- 239000002002 slurry Substances 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 229940054269 sodium pyruvate Drugs 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 210000004304 subcutaneous tissue Anatomy 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- PRDFBSVERLRRMY-UHFFFAOYSA-N 2'-(4-ethoxyphenyl)-5-(4-methylpiperazin-1-yl)-2,5'-bibenzimidazole Chemical compound C1=CC(OCC)=CC=C1C1=NC2=CC=C(C=3NC4=CC(=CC=C4N=3)N3CCN(C)CC3)C=C2N1 PRDFBSVERLRRMY-UHFFFAOYSA-N 0.000 description 1
- 241000186361 Actinobacteria <class> Species 0.000 description 1
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 208000012639 Balance disease Diseases 0.000 description 1
- 101100298998 Caenorhabditis elegans pbs-3 gene Proteins 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- 239000012594 Earle’s Balanced Salt Solution Substances 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical compound [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- OWIKHYCFFJSOEH-UHFFFAOYSA-N Isocyanic acid Chemical compound N=C=O OWIKHYCFFJSOEH-UHFFFAOYSA-N 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 101100181592 Mus musculus Lep gene Proteins 0.000 description 1
- 241001629494 Nephelium Species 0.000 description 1
- 244000183278 Nephelium litchi Species 0.000 description 1
- 235000015742 Nephelium litchi Nutrition 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 241001093760 Sapindaceae Species 0.000 description 1
- 244000000231 Sesamum indicum Species 0.000 description 1
- 235000003434 Sesamum indicum Nutrition 0.000 description 1
- 206010040954 Skin wrinkling Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241000223259 Trichoderma Species 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- 229940069521 aloe extract Drugs 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- HAMNKKUPIHEESI-UHFFFAOYSA-N aminoguanidine Chemical compound NNC(N)=N HAMNKKUPIHEESI-UHFFFAOYSA-N 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 229940035674 anesthetics Drugs 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 239000000058 anti acne agent Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000001139 anti-pruritic effect Effects 0.000 description 1
- 230000002682 anti-psoriatic effect Effects 0.000 description 1
- 230000001153 anti-wrinkle effect Effects 0.000 description 1
- 229940124340 antiacne agent Drugs 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003908 antipruritic agent Substances 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 229960000271 arbutin Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 235000015173 baked goods and baking mixes Nutrition 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 239000007844 bleaching agent Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 238000011095 buffer preparation Methods 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001765 catechin Chemical class 0.000 description 1
- 238000000423 cell based assay Methods 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 229950001002 cianidanol Drugs 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 210000004177 elastic tissue Anatomy 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 229910001448 ferrous ion Inorganic materials 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 235000012055 fruits and vegetables Nutrition 0.000 description 1
- 229940074391 gallic acid Drugs 0.000 description 1
- 235000004515 gallic acid Nutrition 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 238000003125 immunofluorescent labeling Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000003262 industrial enzyme Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 239000002917 insecticide Substances 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 150000002576 ketones Chemical group 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000002932 luster Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000037323 metabolic rate Effects 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 229940057059 monascus purpureus Drugs 0.000 description 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 1
- LPUQAYUQRXPFSQ-DFWYDOINSA-M monosodium L-glutamate Chemical compound [Na+].[O-]C(=O)[C@@H](N)CCC(O)=O LPUQAYUQRXPFSQ-DFWYDOINSA-M 0.000 description 1
- 235000013923 monosodium glutamate Nutrition 0.000 description 1
- 239000004223 monosodium glutamate Substances 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 229940100629 oral lozenge Drugs 0.000 description 1
- 239000005416 organic matter Substances 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- NCAIGTHBQTXTLR-UHFFFAOYSA-N phentermine hydrochloride Chemical compound [Cl-].CC(C)([NH3+])CC1=CC=CC=C1 NCAIGTHBQTXTLR-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000007788 roughening Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 230000037380 skin damage Effects 0.000 description 1
- 230000037393 skin firmness Effects 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- 235000011008 sodium phosphates Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 239000003860 topical agent Substances 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 238000003260 vortexing Methods 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000003871 white petrolatum Substances 0.000 description 1
- 239000003357 wound healing promoting agent Substances 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/77—Sapindaceae (Soapberry family), e.g. lychee or soapberry
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/19—Preparation or pretreatment of starting material involving fermentation using yeast, bacteria or both; enzymatic treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/85—Products or compounds obtained by fermentation, e.g. yoghurt, beer, wine
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Botany (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Medical Informatics (AREA)
- Diabetes (AREA)
- Birds (AREA)
- Dermatology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Child & Adolescent Psychology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
- Cosmetics (AREA)
Abstract
Description
本發明是有關於一種用於提升植物中效性成分含量的發酵方法。 The present invention relates to a fermentation method for increasing the content of plant neutral components.
脂肪為人體內的必要成分,但過度的脂肪成分對人體會造成損害。國家經濟愈來愈起飛的國家,肥胖問題只增不減,因此以亞洲區來看,中國會是下一波肥胖問題增加幅度大幅上升的國家。 Fat is an essential component in the human body, but excessive fat content can cause damage to the human body. In countries where the national economy is taking off, the obesity problem is only increasing. Therefore, from the perspective of the Asian region, China will be the next wave of countries where the increase in obesity problems will increase sharply.
另外,台灣目前已成為為「亞洲第一胖」的國家,18歲以上國民中,男性體重過重之比例為51.1%,女性體重過重之比例為35.8%,且比例還在上升中,甚至體重過重的年齡層也是逐年下降,中小學生體重過重的比例已上升至25%以上,是全球排名第八高的區域。因此肥胖是目前亟需解決的問題。 In addition, Taiwan has now become "the fattest country in Asia." Among the people over 18 years old, the proportion of men who are overweight is 51.1%, and the proportion of women who are overweight is 35.8%, and the proportion is still rising, even being overweight. The age group is also declining year by year, and the proportion of overweight students in elementary and middle schools has risen to more than 25%, making it the eighth-highest region in the world. Therefore, obesity is a problem that needs to be solved urgently.
除此之外,醣化反應(glycation)與皮膚與體內老化相關,更與危害國人健康甚巨的糖尿病有關。醣化反應的本質就是梅納反應(Maillard reaction)或稱為羰胺褐變反應(carbonyl-amine browning),這是糖的醛(酮)基與含胺基物質(例如蛋白質、胜肽、胺基酸、磷脂、核酸或上述之衍生物)的胺基之間的一種非酵素性醣化(nonenzymatic glycosylation;glycation)反應。長期處於高血糖症狀下,會引起葡萄糖自動氧化與蛋白質糖化作用,形成高度醣化終產物(advanced glycation end products,AGEs)。而AGEs更可引起多種老化疾病,例如皮膚皺紋、白內障、粥狀動脈硬化、腎臟衰竭等。 In addition, glycation is related to the aging of the skin and the body, and it is also related to diabetes, which is very harmful to the health of Chinese people. The essence of saccharification reaction is Maillard reaction or carbonyl-amine browning, which is the combination of aldehyde (ketone) group of sugar and amine-containing substances (such as protein, peptide, amine group). A nonenzymatic glycosylation (glycation) reaction between the amine groups of acids, phospholipids, nucleic acids, or derivatives of the above. Under the symptoms of hyperglycemia for a long time, it will cause glucose auto-oxidation and protein glycation to form advanced glycation end products (AGEs). And AGEs can cause a variety of aging diseases, such as skin wrinkles, cataracts, atherosclerosis, kidney failure and so on.
皮膚組織是由表皮、真皮及皮下組織所構成,其中真皮含有大量膠原蛋白及玻尿酸,而與皮膚之保水性及彈力息息相關。人類皮膚會隨著年紀、生理因素或環境因素,而有氧化、老化、膚質粗糙或產生皺紋等現象,如 正常年輕人的皮膚都具一定的彈性和張力,當表情肌鬆弛後,皮膚會很快復原,使皺紋消失;但進入中年後,皮膚開始明顯老化,皮膚變薄、變硬、乾燥、張力降低;真皮膠原蛋白減少、彈力纖維變性、斷裂,使皮膚的張力和彈性降低,因此,當表情肌鬆弛後,皮膚不能很快復原,久之則使皺紋成形;且隨年齡的增大,皮膚和皮下組織更加鬆弛,加上面部支持組織的萎縮或缺失,以及肌肉的鬆軟,皮膚會在重力的作用下發生滑墜,形成更深的皺紋。而肌膚粗糙係由於乾燥、紫外線、清潔劑或化學物質等刺激性物質等外在重要因素,或激素平衡之紊亂等內在重要因素而產生之肌膚困擾,並伴隨角質層屏障功能之下降、角質層水分量之下降、表皮代謝回轉之亢進、鱗屑之產生而角質粗糙化等現象。因此皮膚上的細胞若失去彈性及保濕功能,會引起皮膚褶皺、乾燥及失去光澤等現象。 Skin tissue is composed of epidermis, dermis and subcutaneous tissue. The dermis contains a lot of collagen and hyaluronic acid, which are closely related to the water retention and elasticity of the skin. Human skin will experience oxidation, aging, rough skin or wrinkles with age, physiological factors or environmental factors, such as Normal young people’s skin has a certain degree of elasticity and tension. When the expression muscles relax, the skin will quickly recover and the wrinkles will disappear; but after entering middle age, the skin begins to age significantly, the skin becomes thinner, harder, dry, and tensioned. Decrease; dermal collagen decreases, elastic fibers degeneration, and breakage, which reduces the tension and elasticity of the skin. Therefore, when the expression muscles are relaxed, the skin cannot recover quickly, and wrinkles are formed over time; and with age, the skin becomes weaker The subcutaneous tissue is more relaxed, coupled with the atrophy or lack of facial support tissues, and the softness of muscles, the skin will fall under the action of gravity, forming deeper wrinkles. Rough skin is caused by externally important factors such as dryness, ultraviolet rays, cleansers, chemical substances and other irritating substances, or internal important factors such as hormonal balance disorder, and is accompanied by a decline in the barrier function of the stratum corneum. Phenomenon such as the decrease of water content, the increase of epidermal metabolism, the production of scales and the roughening of keratin. Therefore, if the cells on the skin lose their elasticity and moisturizing function, it will cause skin wrinkles, dryness, and loss of luster.
一直以來,發酵食品之製造均仰賴微生物,微生物被接入原料中,在其生長過程會產生所需酵素,將有機物分解變為人類生活上有益物質的過程稱之發酵;所以實際催化此代謝活動進行者乃微生物所產生的酵素。而發酵得到的產品範圍極廣,從極高單價的醫藥級產品,例如降血脂藥物或抗生素,到工業用的酵素,像是澱粉分解、纖維分解、蛋白質分解酵素等;還有食品用的有益微生物,例如乳酸菌、紅麴菌、納豆菌、食藥用菇菌等,以及味精類的調味品,農業用的生物殺蟲劑,像蘇力菌,或者枯草桿菌、放射線菌、木黴菌等拮抗菌類的微生物;甚至,從動物飼料藥劑或直接添加在飼料中的微生物等,到廢棄物回收、各類污染處理及清理用的微生物,以及其他的特殊酵素。特別地,近年來也有研發人員開始對植物(例如蔬果)進行發酵處理,所得到的植物發酵物可用來增進人體健康。因此,人們對於發酵食品的需求已日益增加。 For a long time, the manufacture of fermented food has relied on microorganisms. Microorganisms are integrated into the raw materials. During their growth, they will produce the required enzymes. The process of decomposing organic matter into beneficial substances in human life is called fermentation; therefore, this metabolic activity is actually catalyzed. The performer is the enzyme produced by the microorganism. The range of products obtained by fermentation is extremely wide, ranging from extremely high unit price pharmaceutical-grade products, such as lipid-lowering drugs or antibiotics, to industrial enzymes, such as starch decomposition, fiber decomposition, and proteolytic enzymes; there are also beneficial food products. Microorganisms, such as lactic acid bacteria, red yeast bacteria, natto bacteria, edible and medicinal mushrooms, as well as seasonings of monosodium glutamate, agricultural biological insecticides, such as suli bacteria, or antagonism such as Bacillus subtilis, actinomycetes, and Trichoderma Fungus microorganisms; even, from animal feed medicines or microorganisms directly added to feed, to waste recycling, various types of pollution treatment and cleaning microorganisms, and other special enzymes. In particular, in recent years, some researchers have begun to ferment plants (such as fruits and vegetables), and the obtained plant fermented products can be used to improve human health. Therefore, people's demand for fermented food has increased day by day.
然而,傳統用來製備發酵產品的發酵製程往往需要耗費大量時間來讓微生物生長,且需要工業級的發酵設備,例如發酵槽,成本極高。因此,若能研發出新穎用於發酵植物的方法,且該方法可用於提升啤酒酵母菌的生長速度及植物中效性成分含量,如此對本領域的技術帶來重大突破且可造福有此需求的廣大族群。 However, the traditional fermentation process used to prepare fermented products often takes a lot of time for the growth of microorganisms, and requires industrial-grade fermentation equipment, such as a fermentation tank, which is extremely costly. Therefore, if a novel method for fermenting plants can be developed, and the method can be used to increase the growth rate of brewer's yeast and the content of the effective components of the plant, this will bring a major breakthrough to the technology in the field and benefit those in need The vast ethnic group.
有鑑於此,本發明之目的為提供一種用於發酵植物的方法,包含以下步驟:(a)以水萃取一植物,而得到一植物萃取物;以及(b)將該植物萃取物與一啤酒酵母菌(Saccharomyces cerevisiae)、一胚芽乳酸菌(Lactobacillus plantarum)及一醋酸菌(Acetobacter aceti)依序進行一發酵過程,而得到一植物發酵物,其中該發酵過程包括對該植物萃取物、該啤酒酵母菌、該胚芽乳酸菌及該醋酸菌照射一波長介於620~750nm的紅色光源。 In view of this, the object of the present invention is to provide a method for fermenting plants, comprising the following steps: (a) extracting a plant with water to obtain a plant extract; and (b) combining the plant extract with a beer Saccharomyces cerevisiae , Lactobacillus plantarum , and Acetobacter aceti sequentially undergo a fermentation process to obtain a plant fermentation product, wherein the fermentation process includes the plant extract, the beer yeast The bacteria, the germ lactic acid bacteria, and the acetic acid bacteria irradiate a red light source with a wavelength between 620 nm and 750 nm.
在本發明的一實施例中,該植物為紅毛丹(Nephelium lappaceum)。 In an embodiment of the present invention, the plant is rambutan ( Nephelium lappaceum ).
在本發明的一實施例中,在該萃取之前,根據總重量加入一具有一濃度為10%(w/w)的葡萄糖。 In an embodiment of the present invention, before the extraction, glucose with a concentration of 10% (w/w) is added according to the total weight.
在本發明的一實施例中,該啤酒酵母菌之發酵時間為1至2.5天,該胚芽乳酸菌之發酵時間為1至3天,及該醋酸菌之發酵時間為3至10天。 In an embodiment of the present invention, the fermentation time of the beer yeast is 1 to 2.5 days, the fermentation time of the germ lactic acid bacteria is 1 to 3 days, and the fermentation time of the acetic acid bacteria is 3 to 10 days.
在本發明的一實施例中,該啤酒酵母菌的濃度介於0.01~0.5%(v/v),該胚芽乳酸菌的濃度介於0.01~0.25%(v/v),及該醋酸菌的濃度介於3~10%(v/v)。 In an embodiment of the present invention, the concentration of the saccharomyces cerevisiae is between 0.01 and 0.5% (v/v), the concentration of the germ lactic acid bacteria is between 0.01 and 0.25% (v/v), and the concentration of the acetic acid bacteria Between 3~10%(v/v).
在本發明的一實施例中,該植物與水的重量比為1:5~10。 In an embodiment of the present invention, the weight ratio of the plant to water is 1:5-10.
在本發明的一實施例中,在步驟(a)中,該萃取的溫度介於50至100℃,及該萃取的時間介於0.5至1.5小時。 In an embodiment of the present invention, in step (a), the temperature of the extraction is between 50 and 100° C., and the time of the extraction is between 0.5 and 1.5 hours.
本發明之另一目的為提供一種如前所述的方法用於提升啤酒酵母菌的生長速度及植物中效性成分含量的用途。 Another object of the present invention is to provide an application of the method as described above for increasing the growth rate of Saccharomyces cerevisiae and the content of effective components in plants.
在本發明的一實施例中,該植物是紅毛丹(Nephelium lappaceum),及該效性成分是多酚(polyphenol)。 In an embodiment of the present invention, the plant is rambutan ( Nephelium lappaceum ), and the active ingredient is polyphenol.
本發明之另一目的為提供一種植物發酵物,係藉由一如前所述的方法而製得。 Another object of the present invention is to provide a plant fermented product, which is prepared by a method as described above.
本發明之另一目的為提供一種如前所述的植物發酵物用於製備一護膚及減脂之組成物的用途。 Another object of the present invention is to provide a use of the aforementioned plant fermented product for preparing a skin care and fat-reducing composition.
在本發明的一實施例中,該護膚包括提升肌膚的抗氧化能力、提升肌膚的抗醣化活性及促進彈力蛋白增生。 In an embodiment of the present invention, the skin care includes enhancing the antioxidant capacity of the skin, enhancing the anti-glycation activity of the skin, and promoting the proliferation of elastin.
在本發明的一實施例中,該減脂包括促進脂肪分解及增加瘦體素分泌。 In an embodiment of the present invention, the fat reduction includes promoting lipolysis and increasing leptin secretion.
在本發明的一實施例中,該組成物是呈一醫藥品、一保養品或一食品產品的形式。 In an embodiment of the present invention, the composition is in the form of a medicine, a skin care product or a food product.
本發明之另一目的為提供一種用於提升微生物的生長速度之方法,包含以下步驟:(a)以水萃取一植物,而得到一植物萃取物;以及(b)將該植物萃取物與一微生物進行一發酵過程,而得到一植物發酵物,其中該微生物是一啤酒酵母菌(Saccharomyces cerevisiae)或一醋酸菌(Acetobacter aceti),該發酵過程包括對該植物萃取物及該微生物照射一波長介於620~750nm的紅色光源。 Another object of the present invention is to provide a method for increasing the growth rate of microorganisms, comprising the following steps: (a) extracting a plant with water to obtain a plant extract; and (b) combining the plant extract with a plant extract The microorganism undergoes a fermentation process to obtain a plant fermented product, wherein the microorganism is a Saccharomyces cerevisiae or Acetobacter aceti . The fermentation process includes irradiating the plant extract and the microorganism with a wavelength medium. Red light source at 620~750nm.
在本發明的一實施例中,該植物為紅毛丹(Nephelium lappaceum)。 In an embodiment of the present invention, the plant is rambutan ( Nephelium lappaceum ).
在本發明的一實施例中,在該萃取之前,根據總重量加入一具有一濃度為10%(w/w)的葡萄糖。 In an embodiment of the present invention, before the extraction, glucose with a concentration of 10% (w/w) is added according to the total weight.
在本發明的一實施例中,該微生物之發酵時間為1至3天。 In an embodiment of the present invention, the fermentation time of the microorganism is 1 to 3 days.
在本發明的一實施例中,該啤酒酵母菌的濃度介於0.01~0.5%(v/v),及該醋酸菌的濃度介於5%(v/v)。 In an embodiment of the present invention, the concentration of the beer yeast is between 0.01 and 0.5% (v/v), and the concentration of the acetic acid bacteria is between 5% (v/v).
在本發明的一實施例中,該啤酒酵母菌的生長速度被提升至少47%,及該醋酸菌的生長速度被提升至少22%。 In an embodiment of the present invention, the growth rate of the beer yeast is increased by at least 47%, and the growth rate of the acetic acid bacteria is increased by at least 22%.
綜上所述,本發明用於發酵植物的方法及由該方法所製得的植物發酵物之功效在於:可提升微生物(例如啤酒酵母菌及醋酸菌)的生長速度及植物中效性成分含量,並藉由提升肌膚的抗氧化能力、提升肌膚的抗醣化活性及促進彈力蛋白增生以達到護膚美肌的功效。另一方面,該植物發酵物可藉由促進脂肪分解及增加瘦體素分泌達到減脂的功效。 In summary, the method of the present invention for fermenting plants and the effect of the plant fermented product prepared by the method are: it can increase the growth rate of microorganisms (such as brewer's yeast and acetic acid bacteria) and the content of effective components in plants , And by enhancing the skin's antioxidant capacity, enhancing the skin's anti-glycation activity and promoting the proliferation of elastin to achieve the effect of skin care and beautiful skin. On the other hand, the plant fermented product can achieve the effect of reducing fat by promoting lipolysis and increasing the secretion of leptin.
以下將進一步說明本發明的實施方式,下述所列舉的實施例係用以闡明本發明,並非用以限定本發明之範圍,任何熟習此技藝者,在不脫離本發明之精神和範圍內,當可做些許更動與潤飾,因此本發明之保護範圍當視後附之申請專利範圍所界定者為準。 The following will further explain the implementation of the present invention. The following examples are used to illustrate the present invention and are not intended to limit the scope of the present invention. Anyone familiar with the art will not depart from the spirit and scope of the present invention. Some changes and modifications can be made. Therefore, the scope of protection of the present invention shall be subject to the scope of the attached patent application.
圖1是微生物生長速度檢測的數據圖。 Figure 1 is a data chart of the microbial growth rate detection.
圖2是植物中效性成分含量分析的數據圖,其中***表示與對照組比較,p<0.001。 Figure 2 is a data diagram of the analysis of the content of the effective components in the plant, where *** means compared with the control group, p <0.001.
圖3是本發明方法所製得的植物發酵物在提升肌膚的抗氧化能力上之效用的數據圖,其中*表示與對照組比較,p<0.05。 Fig. 3 is a data chart of the effectiveness of the plant fermented product prepared by the method of the present invention in enhancing the antioxidant capacity of the skin, where * represents the comparison with the control group, and p <0.05.
圖4是本發明方法所製得的植物發酵物在提升肌膚的抗醣化活性上的功效之數據圖,其中*表示與對照組比較,p<0.05。 Fig. 4 is a data diagram of the efficacy of the plant fermented product prepared by the method of the present invention in enhancing the anti-glycation activity of the skin, where * represents the comparison with the control group, p <0.05.
圖5是本發明方法所製得的植物發酵物在促進彈力蛋白增生上的功效之數據圖。 Figure 5 is a data diagram of the efficacy of plant fermented products prepared by the method of the present invention in promoting the proliferation of elastin.
圖6A及圖6B是本發明方法所製得的植物發酵物在促進彈力蛋白增生上的功效之細胞染色圖,其中藍色代表細胞核,綠色代表彈力蛋白。 Figures 6A and 6B are cell staining diagrams showing the effect of plant fermented product prepared by the method of the present invention on promoting the proliferation of elastin, where blue represents the nucleus and green represents elastin.
圖7是本發明方法所製得的植物發酵物在促進脂肪分解上的功效之數據圖,其中*表示與對照組比較,p<0.05。 Fig. 7 is a data chart of the effect of plant fermented product prepared by the method of the present invention on promoting lipolysis, wherein * represents the comparison with the control group, and p <0.05.
圖8是本發明方法所製得的植物發酵物在增加瘦體素分泌上之效用的數據圖。 Fig. 8 is a data chart showing the effect of plant fermented product prepared by the method of the present invention on increasing the secretion of leptin.
圖9是本發明用於提升微生物的生長速度之方法在提升啤酒酵母菌的生長速度上的功效之數據圖。 Fig. 9 is a data diagram showing the efficacy of the method for increasing the growth rate of microorganisms of the present invention in increasing the growth rate of Saccharomyces cerevisiae.
本文中所使用數值為近似值,所有實驗數據皆表示在20%的範圍內,較佳為在10%的範圍內,最佳為在5%的範圍內。 The numerical values used herein are approximate values, and all experimental data are expressed in the range of 20%, preferably in the range of 10%, and most preferably in the range of 5%.
使用Excel軟體進行統計分析。數據以平均值±標準差(SD)表示,個此之間的差異以學生t檢驗(student's t-test)分析。 Use Excel software for statistical analysis. Data mean ± standard deviation (SD) represented by the difference between the two herein by Student t test (student's t -test) analysis.
依據本發明,紅毛丹(Nephelium lappaceum)是無患子科(Sapindaceae)韶子屬(Nephelium)的大型熱帶果樹,馬來文稱之「rambutan」,意為「毛茸茸之物」。成熟的紅毛丹果並非都是紅色的,也有黃色的果子。有的紅毛丹的核的大小近似於芝麻。紅毛丹的味道類似於荔枝,果肉(假種皮)白色,肉質透明多汁,酸甜可口,內藏種子1粒,扁卵形。 According to the present invention, rambutan ( Nephelium lappaceum ) is a large tropical fruit tree belonging to the genus Nephelium in the Sapindaceae family. Ripe rambutan fruits are not all red, but there are also yellow fruits. The core size of some rambutans is similar to that of sesame. The taste of rambutan is similar to that of lychee. The flesh (aril) is white, the flesh is transparent and juicy, sweet and sour, and contains 1 seed, which is flat oval.
如本文中所使用的,用語「啤酒酵母菌(Saccharomyces cerevisiae)」、「胚芽乳酸菌(Lactobacillus plantarum)」以及「醋酸菌(Acetobacter aceti)」分別意欲涵蓋那些為熟習此項技術人士可易於獲得的啤酒酵母菌、胚芽乳酸菌以及醋酸菌(例如,可購自於國內或國外寄存機構者),或者利用本技藝中所慣用的微生物分離方法而從天然來源中所分離純化出的啤酒酵母菌、胚芽乳酸菌以及醋酸菌菌株。 As used in this article, the terms " Saccharomyces cerevisiae ", " Lactobacillus plantarum " and " Acetobacter aceti " are intended to cover beer that can be easily obtained by those skilled in the art. Yeast, germ lactic acid bacteria and acetic acid bacteria (for example, can be purchased from domestic or foreign depository institutions), or beer yeast and germ isolated and purified from natural sources using the usual microbial isolation method in this art Lactic acid bacteria and acetic acid bacteria strains.
依據本發明,醫藥品可利用熟習此技藝者所詳知的技術而被製造成一適合於非經腸道地(parenterally)、口服地(orally)或局部地(topically)投藥的劑型,這包括,但不限於:注射品(injection)[例如,無菌的水性溶液(sterile aqueous solution)或分散液(dispersion)]、無菌的粉末(sterile powder)、錠劑(tablet)、片劑(troche)、口含錠(lozenge)、丸劑(pill)、膠囊(capsule)、分散性粉末(dispersible powder)或細顆粒(granule)、溶液、懸浮液(suspension)、乳劑(emulsion)、糖漿(syrup)、酏劑(elixir)、濃漿(slurry)、外部製劑(external preparation)以及類似之物。 According to the present invention, the medicine can be manufactured into a dosage form suitable for parenterally, orally or topically by using techniques well known to those skilled in the art, including: But not limited to: injection [for example, sterile aqueous solution or dispersion], sterile powder, tablet, troche, oral Lozenge, pill, capsule, dispersible powder or granule, solution, suspension, emulsion, syrup, elixir (elixir), thick slurry (slurry), external preparation (external preparation) and the like.
依據本發明,醫藥品可進一步包含有一被廣泛地使用於藥物製造技術之醫藥上可接受的載劑(pharmaceutically acceptable carrier)。例如,該醫藥上可接受的載劑可包含一或多種選自於下列的試劑:溶劑(solvent)、緩衝液(buffer)、乳化劑(emulsifier)、懸浮劑(suspending agent)、分解劑(decomposer)、崩解劑(disintegrating agent)、分散劑(dispersing agent)、黏結劑(binding agent)、賦形劑(excipient)、安定劑(stabilizing agent)、螯合劑(chelating agent)、稀釋劑(diluent)、膠凝劑(gelling agent)、防腐劑(preservative)、潤濕劑(wetting agent)、潤滑劑(lubricant)、吸收延遲劑(absorption delaying agent)、脂質體(liposome)以及類似之 物。有關這些試劑的選用與數量是落在熟習此項技術之人士的專業素養與例行技術範疇內。 According to the present invention, the medicine may further include a pharmaceutically acceptable carrier which is widely used in medicine manufacturing technology. For example, the pharmaceutically acceptable carrier may include one or more reagents selected from the group consisting of solvent, buffer, emulsifier, suspending agent, decomposer ), disintegrating agent, dispersing agent, binding agent, excipient, stabilizing agent, chelating agent, diluent , Gelling agent, preservative, wetting agent, lubricant, absorption delaying agent, liposome and the like Things. The selection and quantity of these reagents fall within the scope of professionalism and routine techniques of those who are familiar with this technique.
依據本發明,該醫藥上可接受的載劑包含有一選自於由下列所構成之群組中的溶劑:水、生理鹽水(normal saline)、磷酸鹽緩衝生理鹽水(phosphate buffered saline,PBS)、含有醇的水性溶液(aqueous solution containing alcohol)以及它們的組合。 According to the present invention, the pharmaceutically acceptable carrier includes a solvent selected from the group consisting of water, normal saline (normal saline), phosphate buffered saline (PBS), Aqueous solution containing alcohol and combinations thereof.
依據本發明,該醫藥品可以一選自於由下列所構成之群組中的非經腸道途徑(parenteral routes)來投藥:腹膜內注射(intraperitoneal injection)、皮下注射(subcutaneous injection)、表皮內注射(intraepidermal injection)、皮內注射(intradermal injection)、肌肉內注射(intramuscular injection)、靜脈內注射(intravenous injection)以及病灶內注射(intralesional injection)。 According to the present invention, the drug can be administered by a parenteral route selected from the group consisting of: intraperitoneal injection, subcutaneous injection, intradermal injection Injection (intraepidermal injection), intradermal injection (intradermal injection), intramuscular injection (intramuscular injection), intravenous injection (intravenous injection) and intralesional injection (intralesional injection).
依據本發明,醫藥品可利用熟習此技藝者所詳知的技術而被製造成一適合於局部地施用於皮膚上的外部製劑(external preparation),這包括,但不限於:乳劑(emulsion)、凝膠(gel)、軟膏(ointment)、乳霜(cream)、貼片(patch)、擦劑(liniment)、粉末(powder)、氣溶膠(aerosol)、噴霧(spray)、乳液(lotion)、乳漿(serum)、糊劑(paste)、泡沫(foam)、滴劑(drop)、懸浮液(suspension)、油膏(salve)以及繃帶(bandage)。 According to the present invention, the medicine can be manufactured into an external preparation suitable for topical application to the skin using techniques well-known to those skilled in the art. This includes, but is not limited to: emulsion, coagulation Gel, ointment, cream, patch, liniment, powder, aerosol, spray, lotion, milk Serum, paste, foam, drop, suspension, salve and bandage.
依據本發明,該外部製劑是藉由將本發明的醫藥品與一為熟習此項技藝者所詳知的基底(base)相混合而被製備。 According to the present invention, the external preparation is prepared by mixing the medicine of the present invention with a base well known to those skilled in the art.
依據本發明,該基底可包含有一或多種選自於下列的添加劑(additives):水、醇(alcohols)、甘醇(glycol)、碳氫化合物(hydrocarbons)[諸如石油膠(petroleum,jelly)以及白凡士林(white petrolatum)]、蠟(wax)[諸如石蠟(paraffin)以及黃蠟(yellow wax)]、保存劑(preserving agents)、抗氧化劑(antioxidants)、界面活性劑(surfactants)、吸收增強劑(absorption enhancers)、安定劑(stabilizing agents)、膠凝劑(gelling agents)[諸如卡波普®974P(carbopol®974P)、微結晶纖維素(microcrystalline cellulose)以及羧基甲基纖維素(carboxymethylcellulose)]、活性劑(active agents)、保濕劑(humectants)、氣味吸收劑(odor absorbers)、香料(fragrances)、pH調整劑(pH adjusting agents)、螯合劑(chelating agents)、乳化劑 (emulsifiers)、閉塞劑(occlusive agents)、軟化劑(emollients)、增稠劑(thickeners)、助溶劑(solubilizing agents)、滲透增強劑(penetration enhancers)、抗刺激劑(anti-irritants)、著色劑(colorants)以及推進劑(propellants)等。有關這些添加劑的選用與數量是落在熟習此項技術之人士的專業素養與例行技術範疇內。 According to the present invention, the substrate may contain one or more additives selected from the following: water, alcohols, glycols, hydrocarbons (such as petroleum jelly) and White petrolatum], wax (such as paraffin and yellow wax), preserving agents, antioxidants, surfactants, absorption enhancers ( absorption enhancers), stabilizers (stabilizing agents), gelling agent (gelling agents) [such as Carbopol ® 974P (carbopol ® 974P), microcrystalline cellulose (microcrystalline cellulose) and carboxymethyl cellulose (carboxymethylcellulose)], Active agents, humectants, odor absorbers, fragrances, pH adjusting agents, chelating agents, emulsifiers, occlusive agents (occlusive agents), emollients, thickeners, solubilizing agents, penetration enhancers, anti-irritants, colorants and propellants (propellants) and so on. The selection and quantity of these additives fall within the scope of professionalism and routine techniques of those who are familiar with this technology.
依據本發明,保養品可進一步包含有一被廣泛地使用於保養品製造技術之可接受的佐劑(acceptable adjuvant)。例如,該可接受的佐劑可包含有一或多種選自於下列的試劑:溶劑、膠凝劑、活性劑、防腐劑、抗氧化劑、遮蔽劑(screening agent)、螯合劑、界面活性劑、染色試劑(coloring agent)、增稠劑(thickening agent)、填料(filler)、香料以及氣味吸收劑。有關這些試劑的選用與數量是落在熟習此項技術之人士的專業素養與例行技術範疇內。 According to the present invention, the skin care product can further include an acceptable adjuvant that is widely used in skin care product manufacturing technology. For example, the acceptable adjuvant may contain one or more agents selected from the group consisting of solvents, gelling agents, active agents, preservatives, antioxidants, screening agents, chelating agents, surfactants, dyes Coloring agent, thickening agent, filler, fragrance and odor absorber. The selection and quantity of these reagents fall within the scope of professionalism and routine techniques of those who are familiar with this technique.
依據本發明,保養品可利用熟習此技藝者所詳知的技術而被製造成一適合於護膚(skincare)或化妝(makeup)的形式,這包括,但不限於:水性溶液(aqueous solution)、水-醇溶液(aqueous-alcohol solution)或油性溶液(oily solution)、呈水包油型(oil-in-water type)、油包水型(water-in-oil type)或複合型之乳劑、凝膠、軟膏、乳霜、面膜(mask)、貼片、貼布(pack)、擦劑、粉末、氣溶膠、噴霧、乳液、乳漿、糊劑、泡沫、分散液、滴劑、慕斯(mousse)、防曬油(sunblock)、化妝水(tonic water)、粉底(foundation)、卸妝產品(makeup remover products)、肥皂(soap)以及其他身體清潔產品(body cleansing products)等。 According to the present invention, the skin care product can be manufactured into a form suitable for skincare or makeup by using techniques well known to those skilled in the art. This includes, but is not limited to: aqueous solution, water -Aqueous-alcohol solution or oily solution, oil-in-water type, water-in-oil type or compound emulsion, gel Glue, ointment, cream, mask, patch, pack, liniment, powder, aerosol, spray, lotion, emulsion, paste, foam, dispersion, drops, mousse ( mousse, sunblock, tonic water, foundation, makeup remover products, soap, and other body cleansing products.
依據本發明,保養品亦可與一或多種選自於下列之已知活性的外用劑(external use agents)一起合併使用:美白劑(whitening agents)[諸如維生素A酸(tretinoin)、兒茶素(catechin)、麴酸、熊果苷以及維生素C]、保濕劑、抗發炎劑(anti-inflammatory agents)、殺菌劑(bactericides)、紫外線吸收劑(ultraviolet absorbers)、植物萃取物(plant extracts)[諸如蘆薈萃取物(aloe extract)]、皮膚營養劑(skin nutrients)、麻醉劑(anesthetics)、抗痘劑(anti-acne agents)、止癢劑(antipruritics)、止痛劑(analgesics)、抗皮膚炎劑(antidermatitis agents)、抗過角化劑(antihyperkeratolytic agents)、抗乾皮膚劑(anti-dry skin agents)、抗汗劑(antipsoriatic agents)、抗老化劑(antiaging agents)、抗皺劑(antiwrinkle agents)、抗皮脂溢出劑(antiseborrheic agents)、傷口治療劑(wound-healing agents)、皮質類固 醇(corticosteroids)以及激素(hormones)。有關這些外用劑的選用與數量是落在熟習此項技術之人士的專業素養與例行技術範疇內。 According to the present invention, skin care products can also be used in combination with one or more external use agents with known activities selected from the following: whitening agents (such as tretinoin, catechins) (catechin), koji acid, arbutin and vitamin C], moisturizers, anti-inflammatory agents, bactericides, ultraviolet absorbers, plant extracts [ Such as aloe extract, skin nutrients, anesthetics, anti-acne agents, antipruritics, analgesics, and anti-dermatitis agents (antidermatitis agents), antihyperkeratolytic agents, anti-dry skin agents, antipsoriatic agents, antiaging agents, antiwrinkle agents, Antiseborrheic agents, wound-healing agents, corticosteroids Corticosteroids and hormones. The selection and quantity of these topical agents fall within the scope of professionalism and routine techniques of those who are familiar with this technique.
依據本發明,食品產品可被當作食品添加物(food additive),藉由習知方法於原料製備時添加,或是於食品的製作過程中添加,而與任一種可食性材料配製成供人類與非人類動物攝食的食品產品。 According to the present invention, a food product can be used as a food additive, which can be added during the preparation of raw materials by a conventional method, or added during the production process of the food, and formulated with any edible material for supply Food products consumed by humans and non-human animals.
依據本發明,食品產品的種類包括但不限於:飲料(beverages)、發酵食品(fermented foods)、烘培產品(bakery products)、健康食品(health foods)以及膳食補充品(dietary supplements)。 According to the present invention, the types of food products include, but are not limited to: beverages, fermented foods, bakery products, health foods, and dietary supplements.
首先,將來自泰國南部羅勇市的紅毛丹(Nephelium lappaceum)果汁以1:5~10的重量比例與水混合,並根據總重量加入一具有一濃度為10%(w/w)的葡萄糖。接著,在50℃~100℃下萃取0.5~1.5小時,得到一植物萃取物。 First, the rambutan (Nephelium lappaceum ) juice from Rayong, southern Thailand is mixed with water in a weight ratio of 1:5-10, and glucose with a concentration of 10% (w/w) is added according to the total weight. Then, extract at 50°C-100°C for 0.5-1.5 hours to obtain a plant extract.
接著,在植物萃取物的培養基殖入啤酒酵母菌(Saccharomyces cerevisiae)BCRC 20271開始發酵後,每24小時取出1mL之菌液,經序列稀釋後,將菌液塗於酵母腖葡萄糖(Yeast peptone dextrose,YPD)盤上,其中發酵全程照射波長介於620~750nm(較佳為635nm)的紅色LED光源,得到照射紅色LED光源的植物發酵物。之後,將照射紅色LED光源的植物發酵物使用作為實驗組,比較組之植物發酵物的製備方法大致上是相同於實驗組,不同之處在於:以波長介於400~450nm的藍光取代紅色LED光源;至於對照組之植物發酵物的製備方法大致上是相同於實驗組,不同之處在於:以自然光取代紅色LED光源。接著,將塗有菌液之YPD盤放置於攝氏30℃之培養箱培養48小時,然後計算菌落以評估啤酒酵母菌生長速度。實驗結果顯示於圖1。 Then, after the plant extract culture medium is colonized with Saccharomyces cerevisiae BCRC 20271 and the fermentation begins, 1 mL of the bacterial liquid is taken out every 24 hours, and after serial dilution, the bacterial liquid is applied to Yeast peptone dextrose, YPD) plate, wherein the whole fermentation process is irradiated with a red LED light source with a wavelength of 620~750nm (preferably 635nm) to obtain the plant fermented product irradiated with the red LED light source. After that, the plant fermented product irradiated with the red LED light source was used as the experimental group. The preparation method of the plant fermented product of the comparison group was roughly the same as that of the experimental group, except that the red LED was replaced by blue light with a wavelength of 400~450nm Light source: As for the preparation method of the plant fermented product of the control group, the preparation method is roughly the same as that of the experimental group, except that the red LED light source is replaced by natural light. Next, place the YPD plate coated with bacterial solution in an incubator at 30°C for 48 hours, and then count the colonies to evaluate the growth rate of the brewer's yeast. The experimental results are shown in Figure 1.
圖1是微生物生長速度檢測的數據圖。由圖1可見,與對照組及比較組相較之下,實驗組的啤酒酵母菌生長速度有顯著的提升。特別地,於發酵製程中,全程照射波長620~750nm之紅色LED光源可提升啤酒酵母菌生長速度47%(與對照組比較),反之照射自然光與藍光則無提升生長速度之效果。本實施例的結果顯示,在發酵植物過程中照射紅色LED光源可有效提升啤酒酵母菌的生長速度。 Figure 1 is a data chart of the microbial growth rate detection. It can be seen from Figure 1 that compared with the control group and the comparison group, the growth rate of S. cerevisiae in the experimental group has been significantly improved. In particular, during the fermentation process, irradiating a red LED light source with a wavelength of 620 to 750 nm throughout the fermentation process can increase the growth rate of beer yeast by 47% (compared to the control group), whereas irradiating natural light and blue light has no effect on the growth rate. The results of this embodiment show that irradiating a red LED light source during the fermentation of plants can effectively increase the growth rate of brewer's yeast.
首先,製備標準溶液,將10g的沒食子酸(gallic acid)溶於水中並添加10mL的體積至量瓶中。接著,分別配製0μL/mL、20μL/mL、40μL/mL、60μL/mL、80μL/mL及100μL/mL的標準溶液,接而取100μL的各個標準溶液至具有10mL體積的離心管。之後,添加500μL的佛蕭酚試劑(Folin-Ciocalteu’s phenol reagent)、混合並直立放置3分鐘,接而添加400μL的7.5%碳酸鈉(sodiμM carbonate)、混合並直立放置30分鐘。接著,將200μL的各個反應溶液轉移至96-孔盤中,於750nm下測量吸光值。 First, prepare a standard solution, dissolve 10 g of gallic acid in water and add a volume of 10 mL to a measuring flask. Next, prepare 0 μL/mL, 20 μL/mL, 40 μL/mL, 60 μL/mL, 80 μL/mL, and 100 μL/mL standard solutions, and then take 100 μL of each standard solution to a centrifuge tube having a volume of 10 mL. After that, add 500 μL of Folin-Ciocalteu's phenol reagent, mix and stand upright for 3 minutes, then add 400 μL of 7.5% sodium carbonate (sodi μM carbonate), mix and stand upright for 30 minutes. Then, 200 μL of each reaction solution was transferred to a 96-well plate, and the absorbance was measured at 750 nm.
另外,將實施例1所述之照射紅色LED光源的植物發酵物使用作為實驗組,對照組之植物發酵物的製備方法大致上是相同於實驗組,不同之處在於:以自然光取代紅色LED光源。將實驗組及對照組分別以水予以稀釋五倍並取100mL的體積至微量離心管中。之後,添加500μL的佛蕭酚試劑、混合並直立放置3分鐘,接而添加400μL的7.5%碳酸鈉、混合並直立放置30分鐘。接著,將200μL的各組反應溶液轉移至96-孔盤中,於750nm下測量吸光值。總多酚含量的結果顯示於圖2。 In addition, the plant fermented product irradiated with the red LED light source described in Example 1 was used as the experimental group. The preparation method of the plant fermented product of the control group was roughly the same as that of the experimental group, except that natural light was used instead of the red LED light source. . The experimental group and the control group were respectively diluted five times with water and a volume of 100 mL was transferred to a microcentrifuge tube. After that, add 500 μL of phoschorol reagent, mix and stand upright for 3 minutes, and then add 400 μL of 7.5% sodium carbonate, mix and stand upright for 30 minutes. Then, 200 μL of the reaction solutions of each group were transferred to a 96-well plate, and the absorbance was measured at 750 nm. The results of the total polyphenol content are shown in Figure 2.
圖2是植物中效性成分含量分析的數據圖。由圖2可見,與對照組相較之下,實驗組的總多酚含量有顯著的提升(提升60%)。本實施例的結果顯示,在發酵植物過程中照射紅色LED光源可有效提升植物(即紅毛丹)中效性成分(即總多酚)含量。 Figure 2 is a data diagram of the analysis of the content of effective components in plants. It can be seen from Figure 2 that compared with the control group, the total polyphenol content of the experimental group has a significant increase (up 60%). The results of this embodiment show that irradiating a red LED light source during the fermentation of plants can effectively increase the content of neutral components (that is, total polyphenols) in plants (that is, rambutans).
基於實施例1及實施例2的結果,本發明決定利用紅色LED光源進行植物發酵物的製備。首先,將來自泰國南部羅勇市的紅毛丹(Nephelium lappaceum)果汁以1:5~10的重量比例與水混合,並根據總重量加入一具有一濃度為10%(w/w)的葡萄糖。接著,在50℃~100℃下萃取0.5~1.5小時,得到一植物萃取物。將該植物萃取物冷卻至室溫供後續三段式發酵使用。三段式發酵係為把植物萃取物依序接種0.01~0.5%(v/v)啤酒酵母菌(Saccharomyces cerevisiae)BCRC 20271發酵1~2.5天;接種0.01~0.25%(v/v)胚芽乳酸菌(Lactobacillus plantarum)TCI028(於民國106年12月13日寄存於食品工業發展研究所的生物資 源保存及研究中心,寄存編號BCRC910805)發酵1~3天;接種3~10%(v/v)醋酸菌(Acetobacter aceti)BCRC 11688(以上菌株皆是購自於台灣的食品工業發展研究所(Food Industry Research and Development Institute,FIRDI)的生物資源保存及研究中心(Biosource Collection and Research Center,BCRC))發酵3~10天,並於發酵全程照射波長介於620~750nm(較佳為635nm)的紅色LED光源。之後,於45℃~70℃下減壓濃縮,接而以200~400網目(mesh)的網篩過濾。接著,添加40~70%異麥芽寡糖後滅菌,得到植物發酵物。 Based on the results of Example 1 and Example 2, the present invention decided to use a red LED light source to prepare plant fermented products. First, the rambutan (Nephelium lappaceum ) juice from Rayong, southern Thailand is mixed with water in a weight ratio of 1:5-10, and glucose with a concentration of 10% (w/w) is added according to the total weight. Then, extract at 50°C-100°C for 0.5-1.5 hours to obtain a plant extract. The plant extract is cooled to room temperature for subsequent three-stage fermentation. The three-stage fermentation system is to inoculate plant extracts in sequence with 0.01~0.5% (v/v) Saccharomyces cerevisiae (Saccharomyces cerevisiae) BCRC 20271 for 1~2.5 days; inoculate 0.01~0.25% (v/v) germ lactic acid bacteria ( Lactobacillus plantarum ) TCI028 (deposited at the Biological Resources Preservation and Research Center of the Food Industry Development Institute on December 13, 2006, deposit number BCRC910805) Fermentation for 1~3 days; inoculation of 3~10% (v/v) acetic acid bacteria ( Acetobacter aceti ) BCRC 11688 (the above strains are all purchased from the Biosource Collection and Research Center (BCRC) of the Food Industry Research and Development Institute (FIRDI) in Taiwan) fermentation 3 ~10 days, and irradiate a red LED light source with a wavelength of 620~750nm (preferably 635nm) throughout the fermentation process. After that, it was concentrated under reduced pressure at 45°C to 70°C, and then filtered with a mesh of 200 to 400 mesh. Next, add 40 to 70% isomalto-oligosaccharides and sterilize to obtain a plant fermented product.
據報導,35歲過後,人體抗氧化能力大幅下降,自由基大量堆積,肌膚快速老化。因此,本實施例探討依據實施例3方法所製得的植物發酵物可否提升肌膚的抗氧化能力。使用降低鐵氧化之能力(Ferric reducing antioxidant power,FRAP)的比色法,以測定待測物的抗氧化能力;其中,係利用具有還原活性的待測物能夠將鐵離子(Fe3+)還原成亞鐵離子(Fe2+),而溶液顏色回由紅褐色轉變為綠色,而該綠色化合物的深淺與還原能力呈正比,因此可用於定量待測物的還原活性。 According to reports, after the age of 35, the body's antioxidant capacity drops drastically, free radicals accumulate, and skin ages rapidly. Therefore, this example explores whether the plant fermented product prepared according to the method of Example 3 can improve the antioxidant capacity of the skin. Use Ferric reducing antioxidant power (FRAP) colorimetry to determine the antioxidant capacity of the test substance; among them, the test substance with reducing activity can be used to reduce iron ions (Fe 3+ ) It becomes ferrous ion (Fe 2+ ), and the color of the solution turns from reddish brown to green. The intensity of the green compound is proportional to the reducing power, so it can be used to quantify the reducing activity of the test substance.
首先,利用已知具有還原活性的抗壞血酸製作標準曲線。精密秤取10mL的L-抗壞血酸(L-Ascorbic acid,Vit C,維他命C,購自Sigma,美國,編號A5960-25g),置於10mL的容量瓶中,再加入ddH2O定量至10mL,配製為1mg/mL之L-抗壞血酸。接著,取1mL配好的L-抗壞血酸置於10mL的容量瓶中,再加入ddH2O定量至10mL,配製為1μg/mL之L-抗壞血酸,並將該100μg/mL的L-抗壞血酸進行系列稀釋成0、10、20、40、60、80、及100μL/mL之L-抗壞血酸(如表1所示),並分別取250μL之各濃度的標準溶液至試管中,再各加入250μL之磷酸鹽緩衝溶液(以無水磷酸二氫鈉(NaH2PO4,購自J.T.Baker,編號3828-01)及磷酸氫二鈉(Na2HPO4,購自Sigma,編號04270)以1:1比例混合所配製而成)以震盪儀(Vortex)混合均勻後,加入250μL之1%的赤血鹽(Potassium ferricyanide,K3Fe(CN),購自Sigma,編號244023)以震盪儀混合均勻後,於50℃水浴槽中加熱20分鐘,再加入250μL之10%的三氯醋酸(Trichloroacetic acid,TCA,CCl3COOH,購自J.T Baker,編號0414-01)以震盪儀混合均勻後,以300g離心10 分鐘,並注意取出時不要搖晃,接著取出300μL的各管反應溶液之上清液,再加入300μL之ddH2O及120μL之1%的氯化鐵(FeCl3,購自Alfa Aesar,編號A16231)以震盪儀混合均勻後反應10分鐘,並測量其於700nm之吸光值,以繪製標準溶液之迴歸曲線公式。 First, a standard curve is prepared using ascorbic acid, which is known to have reducing activity. Accurately weigh 10mL of L-Ascorbic acid (L-Ascorbic acid, Vit C, Vitamin C, purchased from Sigma, USA, No. A5960-25g), place it in a 10mL volumetric flask, add ddH 2 O to quantify to 10mL, and prepare It is 1mg/mL of L-ascorbic acid. Next, take 1mL of the prepared L-ascorbic acid and place it in a 10mL volumetric flask, then add ddH 2 O to quantify to 10mL, prepare 1μg/mL L-ascorbic acid, and dilute the 100μg/mL L-ascorbic acid serially Make 0, 10, 20, 40, 60, 80, and 100μL/mL L-ascorbic acid (as shown in Table 1), and respectively take 250μL of each concentration standard solution into the test tube, and then add 250μL of phosphate to each Buffer solution (prepared by mixing anhydrous sodium dihydrogen phosphate (NaH 2 PO 4 , purchased from JTBaker, code 3828-01) and disodium hydrogen phosphate (Na 2 HPO 4 , purchased from Sigma, code 04270) in a ratio of 1:1 After mixing with a vibrator (Vortex), add 250μL of 1% red blood salt (Potassium ferricyanide, K 3 Fe (CN), purchased from Sigma, No. 244023) and mix with a vibrator at 50°C. Heat in a water bath for 20 minutes, then add 250 μL of 10% trichloroacetic acid (TCA, CCl 3 COOH, purchased from JT Baker, No. 0414-01), mix well with a shaker, and centrifuge at 300 g for 10 minutes. And be careful not to shake when taking it out, then take out 300μL of the supernatant of each tube reaction solution, then add 300μL of ddH 2 O and 120μL of 1% ferric chloride (FeCl 3 , purchased from Alfa Aesar, number A16231) to shake After mixing the instrument evenly, let it react for 10 minutes, and measure its absorbance at 700nm to draw the regression curve formula of the standard solution.
接著,將實施例3所製得的植物發酵物使用作為實驗組,比較組之植物發酵物的製備方法大致上是相同於實施例3所述之用於發酵植物的方法,不同之處在於:以自然光取代紅色LED光源。此外,將實施例3的植物萃取物使用作為對照組。各組樣品稀釋20倍後進行後續實驗。之後,分別取250μL之各組樣品於10mL之玻璃試管中,再分別加入250μL之磷酸鹽緩衝溶液以震盪儀混合均勻後,加入250μL之1%的赤血鹽以震盪儀混合均勻後,於50℃水浴槽中加熱20分鐘,再加入250μL之10%的三氯醋酸以震盪儀混合均勻後,以300g離心10分鐘,並注意取出時不要搖晃,接著取出300μL的各管反應溶液之上清液,再加入300μL之ddH2O及120μL之1%的氯化鐵以震盪儀混合均勻後反應10分鐘,並測量其於700nm之吸光值,再以上述之標準溶液的迴歸曲線公式,以內差法算出濃度後,再回乘稀釋倍數以取得各組樣品的還原能力。本實施例的結果顯示於圖3。 Next, the plant fermented product prepared in Example 3 was used as the experimental group. The preparation method of the plant fermented product of the comparative group was roughly the same as the method for fermenting plants described in Example 3, except that: Replace the red LED light source with natural light. In addition, the plant extract of Example 3 was used as a control group. After the samples of each group were diluted 20 times, follow-up experiments were carried out. After that, take 250μL of each group of samples into a 10mL glass test tube, then add 250μL of phosphate buffer solution and mix well with a shaker, add 250μL of 1% red blood salt and mix well with a shaker, and then mix well with a shaker. Heat in a water bath at ℃ for 20 minutes, then add 250μL of 10% trichloroacetic acid to mix well with a shaker, centrifuge at 300g for 10 minutes, and take care not to shake when taking it out, then take out 300μL of the supernatant of each tube reaction solution , Then add 300 μL of ddH 2 O and 120 μL of 1% ferric chloride, mix well with a shaker, and react for 10 minutes, and measure its absorbance at 700 nm, and then use the regression curve formula of the above standard solution to use the inner difference method After calculating the concentration, multiply the dilution factor to obtain the reduction ability of each group of samples. The results of this example are shown in FIG. 3.
圖3是本發明方法所製得的植物發酵物在提升肌膚的抗氧化能力上之效用的數據圖。由圖3可見,與對照組及比較組相較之下,實驗組的還原能力有顯著的提升。特別地,與對照組比較,實驗組的還原能力提升57%。本實施例的結果顯示,本發明用於發酵植物的方法所製得的植物發酵物可有效提升肌膚的抗氧化能力。 Fig. 3 is a data diagram showing the effectiveness of the plant fermented product prepared by the method of the present invention in enhancing the antioxidant capacity of the skin. It can be seen from Figure 3 that compared with the control group and the comparison group, the reduction ability of the experimental group has been significantly improved. In particular, compared with the control group, the reduction ability of the experimental group increased by 57%. The results of this example show that the plant fermented product prepared by the method for fermenting plants of the present invention can effectively enhance the antioxidant capacity of the skin.
本實施例係為了測試本發明用於發酵植物的方法所製得的植物發酵物的抗醣化活性,因此以抑制D-果糖(D-fructose)使膠原蛋白(Collagen)產生醣化的效率,進行醣化活性之定量。醣分子與蛋白交聯形成高度醣化終產物(Advanced glycation end-products,AGEs),引發細胞內氧化壓力,造成肌膚老化受損。首先,將實施例3所製得的植物發酵物使用作為實驗組,比較組1之植物發酵物的製備方法大致上是相同於實施例3所述之用於發酵植物的方法,不同之處在於:以自然光取代紅色LED光源,比較組2的製備方法與實施例3所述之用於發酵植物的方法不同之處在於:以水萃取得到植物萃取物之後沒有進行三段式發酵及紅色LED光源照射。至於對照組的方法則沒有照光及沒有添加植物發酵物或萃取物。將各組樣品稀釋10倍後進行後續實驗。之後,加入0.2mL之含有0.06%之NaN3的60mg/mL之膠原蛋白溶液(以200mM之磷酸鈉緩衝液配製,pH 7.4),並與0.2mL的1.5M D-果糖(以200mM之磷酸鈉緩衝液配製,pH 7.4)溶液均勻混合,取出0.1mL混合溶液作為原點產物,並將剩餘的混合溶液於50℃下反應24小時後,取出0.1mL作為終點產物,再分別測量原點產物與終點產物於激發波長360nm、放射波長460nm的螢光數值,其中已知胺基胍(Aminoguanidine,AG)具有抑制醣化作用的功效。最後,以下列公式計算清除高度醣化終產物(AGEs)能力之效率,以代表其抗醣化作用的活性,其中高度醣化終產物生成量越少表示抗醣化活性越高。
This example is to test the anti-saccharification activity of the plant fermented product prepared by the method for fermenting plants of the present invention. Therefore, the efficiency of saccharification of collagen (Collagen) produced by inhibiting D-fructose is used to perform saccharification. Quantification of activity. Sugar molecules and proteins are cross-linked to form advanced glycation end-products (AGEs), which trigger oxidative stress in cells and cause skin aging and damage. First, the plant fermented product prepared in Example 3 was used as the experimental group. The preparation method of the plant fermented product of
本實施例的結果顯示於圖4。圖4是本發明方法所製得的植物發酵物在提升肌膚的抗醣化活性上的功效之數據圖。由圖4可見,與對照組、比較組1及比較組2相較之下,實驗組的醣化比例百分比有顯著的降低。其中,與對照組比較,實驗組的醣化比例百分比減少約55%。本實施例的結果顯示,本發明用於發酵植物的方法所製得的植物發酵物能有效提升其清除高度醣化終產物之能力,並具有優異的提升肌膚之抗醣化活性。
The results of this example are shown in FIG. 4. Figure 4 is a data diagram of the efficacy of plant fermented products prepared by the method of the present invention in enhancing the anti-glycation activity of the skin. It can be seen from Figure 4 that compared with the control group, the
在肌膚中,彈力蛋白跟膠原蛋白相互配合,能幫助支持肌膚的架構,提升肌膚的彈性,加強肌膚的緊實,減少皺紋的產生。因此,本實施例探討依據實施例3方法所製得的植物發酵物可否促進彈力蛋白增生。首先,將實施例3所製得的植物發酵物(濃度為0.0625%)使用作為實驗組,比較組之植物發酵物的製備方法大致上是相同於實施例3所述之用於發酵植物的方法,不同之處在於:以自然光取代紅色LED光源。至於對照組的方法則沒有照光及沒有添加植物發酵物或萃取物。 In the skin, elastin and collagen cooperate with each other to help support the structure of the skin, enhance the elasticity of the skin, strengthen the skin's firmness, and reduce the production of wrinkles. Therefore, this example explores whether the plant fermented product prepared according to the method of Example 3 can promote the proliferation of elastin. First, the plant fermented product (concentration of 0.0625%) prepared in Example 3 was used as the experimental group. The preparation method of the plant fermented product of the comparative group was roughly the same as the method for fermenting plants described in Example 3. , The difference is: replace the red LED light source with natural light. As for the control method, there is no light and no plant fermentation or extracts are added.
接著,進行彈力蛋白(elastin)含量分析,流程如下:使用FastinTM彈力蛋白分析套組(Elastin Assay kit)在6孔盤中用2mL培養基接種1×105細胞/孔,所使用的細胞株為人類皮膚纖維母細胞CCD-966sk(ATCC®編號為CRL-1881),培養基為最低必需培養基(Minimum essential medium,MEM)(添加有10% FBS、1%青黴素/鏈黴素(Penicillin/streptomycin)及1mM丙酮酸鈉(sodium pyruvate)(Gibco)),並在37℃下培育24小時。之後,用2mL培養基處理各組樣品,然後作用48小時。接著,移除培養基並以1X PBS清洗一次,然後以胰蛋白酶(trypsin)處理細胞3分鐘。用培養基停止胰蛋白酶活性,然後轉移至1.5mL管中。接著,用胰蛋白酶收集細胞,然後轉移到1.5mL微量離心管中,以300 xg離心5分鐘,然後以PBS(Gibco)清洗。之後,以300 xg離心5分鐘,然後將細胞沉澱物保留在約300μL的PBS中。接著,向300μL細胞懸浮液中加入100μL的1.0M草酸(oxalic acid),並在加熱塊(heating block)中於100℃作用1小時。向每個試管中加入等體積的彈力蛋白沉澱試劑(Elastin Precipitating Reagent),蓋上試管並短暫渦旋混合,靜置15分鐘以完成沉澱。之後,以10,000 xg離心10分鐘,排放試管的液體內容物,然後透過將倒置的試管輕拍到紙巾上,以除去試管中剩餘的大部分流體。接著,添加1mL染料試劑,透過顛倒試管來混合內容物,然後將試管放在機械振盪器上,作用90分鐘。之後,排空未結合的染料管,彈力蛋白-染料複合物可以觀察到為在試管的底部和內部下壁中的紅棕色沉積物。向每個試管中加入250μL染料解離試劑(Dye Dissociation Reagent),蓋上試管,藉由渦旋混合器將染料釋放到溶液中,確保所有結合的染料都已進入溶液。之後,將每個試管的內容物轉移到96孔盤中,然後將盤放入ELISA讀取儀(BioTek)中,在513nm處測量吸光值。 Next, perform elastin content analysis. The process is as follows: Use Fastin TM Elastin Assay kit to inoculate 1×10 5 cells/well with 2 mL of medium in a 6-well plate. The cell line used is Human skin fibroblasts CCD-966sk (ATCC ® number is CRL-1881), the medium is the minimum essential medium (MEM) (supplemented with 10% FBS, 1% penicillin/streptomycin (Penicillin/streptomycin) and 1mM sodium pyruvate (Gibco)) and incubated at 37°C for 24 hours. After that, the samples of each group were treated with 2 mL of medium, and then acted for 48 hours. Then, the medium was removed and washed once with 1X PBS, and then the cells were treated with trypsin for 3 minutes. Stop trypsin activity with culture medium, then transfer to 1.5 mL tube. Next, the cells were collected with trypsin, then transferred to a 1.5 mL microcentrifuge tube, centrifuged at 300 xg for 5 minutes, and then washed with PBS (Gibco). After that, centrifuge at 300 xg for 5 minutes, and then keep the cell pellet in about 300 μL of PBS. Next, 100 μL of 1.0 M oxalic acid was added to 300 μL of cell suspension, and the mixture was reacted in a heating block at 100° C. for 1 hour. Add an equal volume of Elastin Precipitating Reagent to each test tube, cover the test tube and vortex briefly to mix, and let it stand for 15 minutes to complete the precipitation. After that, centrifuge at 10,000 xg for 10 minutes to drain the liquid content of the test tube, and then gently tap the inverted test tube onto a paper towel to remove most of the remaining fluid in the test tube. Next, add 1 mL of dye reagent, mix the contents by inverting the test tube, and then place the test tube on the mechanical shaker for 90 minutes. After emptying the unbound dye tube, the elastin-dye complex can be observed as a reddish brown deposit in the bottom and inner lower wall of the test tube. Add 250μL of Dye Dissociation Reagent to each test tube, cover the test tube, and release the dye into the solution by vortexing the mixer to ensure that all the bound dye has entered the solution. After that, the contents of each test tube were transferred to a 96-well plate, and then the plate was placed in an ELISA reader (BioTek), and the absorbance was measured at 513nm.
接著,進行彈力蛋白免疫螢光染色,流程如下:在室玻片上每孔接種5×103人類皮膚纖維母細胞CCD-966sk(BCRC編號為60153),培養基為最低必需培養基(Minimum essential medium,MEM)(Eagle)(配於厄爾平衡鹽溶液(Earle's Balanced Salt Solution,Earle's BSS),GIBCO公司,編號41500-034,美國)(添加有0.1mM非必需胺基酸、1.5g/L碳酸氫鈉(sodium bicarbonate)、1mM丙酮酸鈉(sodium pyruvate)(佔比90%)、及10%胎牛血清(FBS)(Gibco)),並培育隔夜。之後,在室溫下用4%多聚甲醛(paraformaldehyde)固定細胞10分鐘,接而以1X PBS清洗3次,然後添加0.2% Triton X-100(配於1X PBS(Gibco))以穿透細胞,並於室溫下作用10分鐘。接著,加入1% BSA(配於1X PBS中),在37℃下封阻1小時,然後以1X PBS清洗3次。之後,加入一次抗體(彈力蛋白抗體(Merck;MAB2503),用1% BSA稀釋,在37℃作用1小時),並以1X PBS清洗3次。接著,加入二次抗體(抗-小鼠-alexa 488抗體(Thermo),用1% BSA稀釋,在37℃作用1小時),並以1X PBS清洗3次。之後,加入Hoechst 33342(Thermo)並於室溫下作用3~5分鐘,然後以1X PBS清洗3次。接著,使用固定膠(mounting gel)固定載玻片,並在螢光顯微鏡下觀察。本實施例的結果顯示於圖5及圖6A與圖6B。 Then, perform elastin immunofluorescence staining. The procedure is as follows: 5×10 3 human skin fibroblasts CCD-966sk (BCRC number 60153) are inoculated on each well of the chamber slide, and the medium is the minimum essential medium (MEM). ) (Eagle) (prepared in Earle's Balanced Salt Solution (Earle's BSS), GIBCO, No. 41500-034, USA) (added with 0.1mM non-essential amino acid, 1.5g/L sodium bicarbonate (sodium bicarbonate), 1mM sodium pyruvate (90%), and 10% fetal bovine serum (FBS) (Gibco)), and incubate overnight. Afterwards, fix the cells with 4% paraformaldehyde at room temperature for 10 minutes, then wash 3 times with 1X PBS, and then add 0.2% Triton X-100 (in 1X PBS (Gibco)) to penetrate the cells , And act for 10 minutes at room temperature. Then, add 1% BSA (in 1X PBS), block at 37°C for 1 hour, and then wash 3 times with 1X PBS. After that, an antibody (elastin antibody (Merck; MAB2503) was added, diluted with 1% BSA, and reacted at 37°C for 1 hour), and washed with 1X PBS for 3 times. Then, the secondary antibody (anti-mouse-alexa 488 antibody (Thermo), diluted with 1% BSA, and reacted at 37° C. for 1 hour) was added, and washed with 1X PBS 3 times. After that, add Hoechst 33342 (Thermo) and incubate at room temperature for 3~5 minutes, then wash 3 times with 1X PBS. Then, the glass slide was fixed with a mounting gel and observed under a fluorescent microscope. The results of this example are shown in Figs. 5 and 6A and 6B.
圖5是本發明方法所製得的植物發酵物在促進彈力蛋白增生上的功效之數據圖。圖6A及圖6B是本發明方法所製得的植物發酵物在促進彈力蛋白增生上的功效之細胞染色圖。由圖5可見,與對照組及比較組相較之下,實驗組的彈力蛋白含量有顯著的提升。其中,與對照組比較,實驗組的彈力蛋白含量提升13%。由圖6A和圖6B可見,本發明方法所製得的植物發酵物在促進彈力蛋白增生上的功效之細胞染色圖,其中藍色代表細胞核,綠色代表彈力蛋白。圖6A為圖5的對照組,圖6B為圖5的實驗組,在螢光顯微鏡下觀察結果顯示,植物發酵物作用下彈力蛋白較多,數據化後如圖5彈力蛋白含量提升13%。本實施例的結果顯示,本發明用於發酵植物的方法所製得的植物發酵物能有效促進彈力蛋白增生。 Figure 5 is a data diagram of the efficacy of plant fermented products prepared by the method of the present invention in promoting the proliferation of elastin. Fig. 6A and Fig. 6B are cell staining diagrams showing the effect of the plant fermented product prepared by the method of the present invention on promoting the proliferation of elastin. It can be seen from Figure 5 that compared with the control group and the comparison group, the elastin content of the experimental group has a significant increase. Among them, compared with the control group, the elastin content of the experimental group increased by 13%. It can be seen from Figure 6A and Figure 6B that the cell staining diagram of the plant fermented product prepared by the method of the present invention in promoting the proliferation of elastin, where blue represents the nucleus and green represents elastin. Fig. 6A is the control group of Fig. 5, and Fig. 6B is the experimental group of Fig. 5. Observation results under a fluorescent microscope show that there is more elastin under the action of plant fermentation products, and the elastin content of Fig. 5 is increased by 13% after data conversion. The results of this example show that the plant fermented product prepared by the method for fermenting plants of the present invention can effectively promote the proliferation of elastin.
本實施例以小鼠骨髓基質細胞進行本發明用於發酵植物的方法所製得的植物發酵物於促進脂肪分解之功效測試。該小鼠骨髓基質細胞OP9係購 自美國典型培養物保藏中心(美國ATCC®),編號CRL-2749TM。該細胞於分化前係培養於前脂肪細胞擴增培養液(Pre-adipocyte Expansion Medium),其中包含90%之最低必需培養基Alpha培養基(minimum essential medium alpha medium,購自Gibco,美國,12100-046)、20%之胎牛血清(Fetal Bovine Serum,購自Gibco,美國),且加入1%之青黴素/鏈黴素(Penicillin-streptomycin,購自Gibco,美國);並使用分化培養液(Differentiation Medium)使小鼠骨髓基質細胞進行分化,其中包含90%最低必需培養基Alpha培養基、20%之胎牛血清,且加入1%之青黴素/鏈黴素。 In this example, mouse bone marrow stromal cells were used to test the efficacy of the plant fermented product prepared by the method for fermenting plants of the present invention in promoting lipolysis. The mouse bone marrow stromal cell OP9 line was purchased from the American Type Culture Collection (ATCC ® ), numbered CRL-2749 TM . The cells are cultured in pre-adipocyte expansion medium (Pre-adipocyte Expansion Medium) before differentiation, which contains 90% of the minimum essential medium Alpha medium (minimum essential medium alpha medium, purchased from Gibco, USA, 12100-046) , 20% fetal bovine serum (Fetal Bovine Serum, purchased from Gibco, USA), and 1% penicillin/streptomycin (Penicillin-streptomycin, purchased from Gibco, USA); and use differentiation medium (Differentiation Medium) Differentiate mouse bone marrow stromal cells, which contains 90% minimum essential medium Alpha medium, 20% fetal bovine serum, and 1% penicillin/streptomycin.
為證實本發明用於發酵植物的方法所製得的植物發酵物具有促進脂肪分解的功效,首先將小鼠骨髓基質細胞分化成脂肪細胞(adipocyte),做法為將8×104小鼠骨髓基質細胞OP9與500μL的前脂肪細胞擴增培養液(Pre-adipocyte Expansion medium)接種於24孔培養盤中,並於37℃下培養7天,每3天更換新鮮的分化培養基。接著,使用顯微鏡(ZEISS)觀察脂滴(lipid droplet)的形成,確保細胞已完全分化。 To demonstrate the present invention for the fermentation of plant obtained fermented plant having the effect of promoting lipolysis, first mouse bone marrow stromal cells to differentiate into adipocytes (adipocyte), practices 8 × 10 4 to mouse bone marrow stromal Cell OP9 and 500 μL of pre-adipocyte expansion medium (Pre-adipocyte Expansion Medium) were seeded in a 24-well culture dish and cultured at 37°C for 7 days, with fresh differentiation medium replaced every 3 days. Next, use a microscope (ZEISS) to observe the formation of lipid droplets to ensure that the cells have fully differentiated.
之後,將OP9細胞分成3組,其中包括1個對照組、1個比較組及1個實驗組。將依據實施例3所述方法所得到的植物發酵物添加至實驗組的細胞中,濃度為0.0625%。比較組細胞添加的物質之製備方法大致上是相同於實施例3所述之用於發酵植物的方法,不同之處在於:以自然光取代紅色LED光源。至於對照組的細胞則不做任何處理。接著,將各組細胞培養7~10天,每3天更換培養基。之後,參照Cayman的以甘油細胞為基礎的分析套組(Glycerol cell-based assay kit)之使用者操作指南,對各組細胞進行甘油分析(glycerol assay)。 After that, OP9 cells were divided into 3 groups, including 1 control group, 1 comparison group and 1 experimental group. The plant fermented product obtained according to the method described in Example 3 was added to the cells of the experimental group at a concentration of 0.0625%. The preparation method of the substances added to the cells of the comparison group is roughly the same as the method for fermenting plants described in Example 3, except that the red LED light source is replaced by natural light. As for the cells in the control group, no treatment was done. Then, the cells of each group were cultured for 7-10 days, and the medium was changed every 3 days. After that, refer to the user manual of Cayman's Glycerol cell-based assay kit to perform glycerol assay on each group of cells.
甘油為脂肪分解的終產物,利用偵測甘油的生成量,檢驗脂肪分解的分解速度。從各孔培養盤中收集細胞培養物上清液,然後取25μL的細胞培養物上清液及標準物(standard)至新的96孔培養盤中。之後,於每孔添加100μL的改製游離甘油分析試劑(reconstituted Free Glycerol Assay Reagent),然後於室溫下反應15分鐘。接著,以ELISA讀取儀(BioTek)讀取各組之OD540nm吸光值。 Glycerin is the final product of lipolysis, and the rate of lipolysis is tested by detecting the amount of glycerol produced. Collect the cell culture supernatant from each well of the culture plate, and then take 25 μL of the cell culture supernatant and standard into a new 96-well culture plate. After that, 100 μL of modified Free Glycerol Assay Reagent was added to each well, and then reacted at room temperature for 15 minutes. Then, the OD 540nm absorbance value of each group was read with an ELISA reader (BioTek).
本實施例的結果顯示於圖7。圖7是本發明方法所製得的植物發酵物在促進脂肪分解上的功效之數據圖。由圖7可見,與對照組及比較組相較之 下,實驗組的油滴含量有顯著的降低。本實施例的結果顯示,本發明用於發酵植物的方法所製得的植物發酵物具有促進脂肪分解的功效。 The results of this example are shown in FIG. 7. Fig. 7 is a data chart of the effect of plant fermented product prepared by the method of the present invention on promoting lipolysis. It can be seen from Figure 7 that compared with the control group and the comparison group Bottom, the oil droplet content of the experimental group was significantly reduced. The results of this example show that the plant fermented product prepared by the method for fermenting plants of the present invention has the effect of promoting fat decomposition.
瘦體素為人體調節體重的重要因子,可抑制食慾及脂肪增生,並增加基礎代謝率,將體脂肪控制於適當範圍中。許多長期肥胖者皆有瘦體素分泌不足的問題,難以減重且容易復胖。因此,本實施例探討依據實施例3方法所製得的植物發酵物可否增加瘦體素分泌。首先,在96孔盤中用200μL前脂肪細胞擴增培養液(Pre-adipocyte Expansion Medium)接種1×104小鼠脂肪細胞(Mus musculus,mouse adipocyte cell)3T3-L1(ATCC®編號為CL-173TM),其中包含90%之杜貝可氏改良的依格氏培養基(Dulbecco's Modified Eagle's Medium,購自Gibco)、10%之牛血清(Bovine Serum,購自Gibco),且加入1%之青黴素/鏈黴素(Penicillin-streptomycin,購自Gibco),然後於37℃下培養48小時。48小時後,去除培養基並添加分化培養液4天(每兩天更換新鮮的分化培養基),其中包含90%杜貝可氏改良的依格氏培養基、10% FBS、1%青黴素/鏈黴素(Penicillin-streptomycin)、1.0μM/mL地塞米松(Dexamethasone,DEXA)(Sigma)、0.5mM/mL甲基異丁基黃嘌呤(Methylisobutylxanthine,IBMX)(Sigma)及1.0μg/mL胰島素(insulin)(Sigma)。4天後,將分化培養液換成脂肪細胞維持培養基(Adipocyte Maintenance Medium)(每兩天更換一次新鮮的維持培養基),其中包含90%杜貝可氏改良的依格氏培養基、10% FBS、1%青黴素/鏈黴素(Penicillin-streptomycin)、及1.0μg/mL胰島素。在開始分化誘導後的7~10天後,細胞已完全分化,然後利用顯微鏡觀察脂滴(lipid droplet)的形成。之後,加入各組樣品(濃度為0.0625%),再作用12天,每48小時更換一次培養基。接著,收集培養基,並使用小鼠LEP(瘦體素)ELISA套組(Mouse LEP(Leptin)ELISA Kit)(Elabscience)確定瘦體素含量。本實施例的結果顯示於圖8。 Leptin is an important factor for the body to regulate body weight. It can suppress appetite and fat hyperplasia, increase the basal metabolic rate, and control body fat within an appropriate range. Many long-term obese people have the problem of insufficient leptin secretion, which makes it difficult to lose weight and easy to gain weight. Therefore, this example explores whether the plant fermented product prepared according to the method of Example 3 can increase the secretion of leptin. First, inoculate 1×10 4 mouse adipocyte cell ( Mus musculus , mouse adipocyte cell) 3T3-L1 (ATCC ® coded CL- 173 TM ), which contains 90% of Dulbecco's Modified Eagle's Medium (Dulbecco's Modified Eagle's Medium, purchased from Gibco), 10% of bovine serum (Bovine Serum, purchased from Gibco), and 1% of penicillin /Streptomycin (Penicillin-streptomycin, purchased from Gibco), and then cultured at 37°C for 48 hours. After 48 hours, remove the medium and add the differentiation medium for 4 days (change the fresh differentiation medium every two days), which contains 90% Dubek's modified Eagle's medium, 10% FBS, 1% penicillin/streptomycin (Penicillin-streptomycin), 1.0μM/mL Dexamethasone (DEXA) (Sigma), 0.5mM/mL Methylisobutylxanthine (IBMX) (Sigma) and 1.0μg/mL insulin (insulin) (Sigma). After 4 days, change the differentiation medium to Adipocyte Maintenance Medium (fresh maintenance medium every two days), which contains 90% Dubek’s modified Eagle’s medium, 10% FBS, 1% penicillin/streptomycin (Penicillin-streptomycin), and 1.0μg/mL insulin. Seven to 10 days after the start of differentiation induction, the cells were fully differentiated, and then the formation of lipid droplets was observed under a microscope. After that, samples of each group (concentration of 0.0625%) were added, and the medium was changed every 48 hours after acting for another 12 days. Next, the culture medium was collected, and the leptin content was determined using the Mouse LEP (Leptin) ELISA Kit (Elabscience). The results of this example are shown in FIG. 8.
圖8是本發明方法所製得的植物發酵物在增加瘦體素分泌上之效用的數據圖。由圖8可見,與對照組及比較組相較之下,實驗組的瘦體素含量有顯著的提升。特別地,與對照組比較,實驗組的瘦體素含量提升30%。本實施 例的結果顯示,本發明用於發酵植物的方法所製得的植物發酵物可有效增加瘦體素分泌。 Fig. 8 is a data chart showing the effect of plant fermented product prepared by the method of the present invention on increasing the secretion of leptin. It can be seen from Figure 8 that compared with the control group and the comparison group, the leptin content of the experimental group has a significant increase. In particular, compared with the control group, the leptin content of the experimental group increased by 30%. This implementation The results of the example show that the plant fermented product prepared by the method for fermenting plants of the present invention can effectively increase the secretion of leptin.
首先,將來自泰國南部羅勇市的紅毛丹(Nephelium lappaceum)果汁以1:5~10的重量比例與水混合,並根據總重量加入一具有一濃度為10%(w/w)的葡萄糖。接著,在50℃~100℃下萃取0.5~1.5小時,得到一植物萃取物。 First, the rambutan (Nephelium lappaceum ) juice from Rayong, southern Thailand is mixed with water in a weight ratio of 1:5-10, and glucose with a concentration of 10% (w/w) is added according to the total weight. Then, extract at 50°C-100°C for 0.5-1.5 hours to obtain a plant extract.
接著,在植物萃取物的培養基殖入0.01~0.5%(v/v)啤酒酵母菌(Saccharomyces cerevisiae)BCRC 20271開始發酵1~3天後,每24小時取出1mL之菌液,經序列稀釋後,將菌液塗於酵母腖葡萄糖(Yeast peptone dextrose,YPD)盤上,其中發酵全程照射波長介於620~750nm(較佳為635nm)的紅色LED光源,得到照射紅色LED光源的植物發酵物。之後,將照射紅色LED光源的植物發酵物使用作為實驗組,比較組之植物發酵物的製備方法大致上是相同於實驗組,不同之處在於:以波長介於400~450nm的藍光取代紅色LED光源;至於對照組之植物發酵物的製備方法大致上是相同於實驗組,不同之處在於:以自然光取代紅色LED光源。接著,將塗有菌液之YPD盤放置於攝氏30℃之培養箱培養48小時,然後計算菌落以評估啤酒酵母菌生長速度。實驗結果顯示於圖9。 Next, the plant extract culture medium is planted with 0.01~0.5% (v/v) Saccharomyces cerevisiae BCRC 20271. After 1~3 days of fermentation, 1mL of bacterial solution is taken out every 24 hours, and after serial dilution, The bacterial liquid is coated on a Yeast peptone dextrose (YPD) plate, and the whole fermentation process is irradiated with a red LED light source with a wavelength of 620-750nm (preferably 635nm) to obtain a plant fermented product that irradiates the red LED light source. After that, the plant fermented product irradiated with the red LED light source was used as the experimental group. The preparation method of the plant fermented product of the comparison group was roughly the same as that of the experimental group, except that the red LED was replaced by blue light with a wavelength of 400~450nm Light source: As for the preparation method of the plant fermented product of the control group, the preparation method is roughly the same as that of the experimental group, except that the red LED light source is replaced by natural light. Next, place the YPD plate coated with bacterial solution in an incubator at 30°C for 48 hours, and then count the colonies to evaluate the growth rate of the brewer's yeast. The experimental results are shown in Figure 9.
圖9是本發明用於提升微生物的生長速度之方法在提升啤酒酵母菌的生長速度上的功效之數據圖。由圖9可見,與對照組及比較組相較之下,實驗組的啤酒酵母菌生長速度有顯著的提升。特別地,於發酵製程中,全程照射波長620~750nm之紅色LED光源(即實驗組)可提升啤酒酵母菌生長速度47%(與對照組比較),反之照射自然光與藍光則無提升生長速度之效果。本實施例的結果顯示,本發明用於提升微生物的生長速度之方法可有效提升啤酒酵母菌的生長速度。 Fig. 9 is a data diagram showing the efficacy of the method for increasing the growth rate of microorganisms of the present invention in increasing the growth rate of Saccharomyces cerevisiae. It can be seen from Fig. 9 that compared with the control group and the comparison group, the growth rate of S. cerevisiae in the experimental group has been significantly improved. In particular, during the fermentation process, irradiating a red LED light source with a wavelength of 620~750nm (the experimental group) throughout the fermentation process can increase the growth rate of beer yeast by 47% (compared to the control group). On the contrary, irradiating natural light and blue light does not increase the growth rate. Effect. The results of this example show that the method for increasing the growth rate of microorganisms of the present invention can effectively increase the growth rate of Saccharomyces cerevisiae.
接著,在植物萃取物的培養基(AAB培養基,添加有0.5%酵母萃取物、0.3%蛋白腖(peptone)及2.5%甘露醇(mannitol))殖入5%(v/v)醋酸菌(Acetobacter aceti)BCRC 11688開始發酵1~3天後,每24小時取出1mL之菌液,經序列稀釋後,將菌液塗於酵母腖葡萄糖(Yeast peptone dextrose,YPD)盤上,其中發酵全程照射波長介於620~750nm(較佳為635nm)的紅色LED光源,得到照
射紅色LED光源的植物發酵物。之後,將照射紅色LED光源的植物發酵物使用作為實驗組,比較組之植物發酵物的製備方法大致上是相同於實驗組,不同之處在於:以波長介於400~450nm的藍光取代紅色LED光源;至於對照組之植物發酵物的製備方法大致上是相同於實驗組,不同之處在於:以自然光取代紅色LED光源。接著,將塗有菌液之YPD盤放置於攝氏30℃之培養箱培養48小時,然後計算菌落以評估醋酸菌生長速度。實驗結果顯示於表2。
Next, in the plant extract medium (AAB medium supplemented with 0.5% yeast extract, 0.3% peptone and 2.5% mannitol), colonize 5% (v/v)
由表2可見,與對照組及比較組相較之下,實驗組的醋酸菌生長速度有顯著的提升。特別地,於發酵製程中,全程照射波長620~750nm之紅色LED光源(即實驗組)可提升醋酸菌生長速度22%(與對照組比較),反之照射自然光與藍光則無提升生長速度之效果。本實施例的結果顯示,本發明用於提升微生物的生長速度之方法可有效提升醋酸菌的生長速度。 It can be seen from Table 2 that compared with the control group and the comparison group, the growth rate of acetic acid bacteria in the experimental group has been significantly improved. In particular, during the fermentation process, irradiating a red LED light source with a wavelength of 620~750nm (the experimental group) can increase the growth rate of acetic acid bacteria by 22% (compared with the control group), while irradiating natural light and blue light has no effect on the growth rate. . The results of this example show that the method for increasing the growth rate of microorganisms of the present invention can effectively increase the growth rate of acetic acid bacteria.
綜上所述,本發明用於發酵植物的方法及由該方法所製得的植物發酵物可提升微生物(例如啤酒酵母菌及醋酸菌)的生長速度及植物中效性成分含量,並藉由提升肌膚的抗氧化能力、提升肌膚的抗醣化活性及促進彈力蛋白增生以達到護膚美肌的功效。另一方面,該植物發酵物可藉由促進脂肪分解及增加瘦體素分泌達到減脂的功效。 In summary, the method for fermenting plants of the present invention and the plant fermented product prepared by the method can increase the growth rate of microorganisms (such as saccharomyces cerevisiae and acetic acid bacteria) and the content of plant neutral components, and by Enhance the skin's antioxidant capacity, enhance the skin's anti-glycation activity, and promote the proliferation of elastin to achieve the effect of skin care and beautiful skin. On the other hand, the plant fermented product can achieve the effect of reducing fat by promoting lipolysis and increasing the secretion of leptin.
以上所述僅為舉例性,而非為限制性者。任何未脫離本發明之精神與範疇,而對其進行之等效修改或變更,均應包含於後附之申請專利範圍中。 The above descriptions are merely illustrative and not restrictive. Any equivalent modifications or alterations that do not depart from the spirit and scope of the present invention should be included in the scope of the appended patent application.
食品工業發展研究所(台灣);民國106年12月13日;編號BCRC910805。 Food Industry Development Research Institute (Taiwan); December 13, 2006; No. BCRC910805.
Claims (18)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962850043P | 2019-05-20 | 2019-05-20 | |
US62/850,043 | 2019-05-20 |
Publications (2)
Publication Number | Publication Date |
---|---|
TW202108164A TW202108164A (en) | 2021-03-01 |
TWI737086B true TWI737086B (en) | 2021-08-21 |
Family
ID=73357911
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW108146489A TWI737086B (en) | 2019-05-20 | 2019-12-18 | Fermentation method for increasing content of effective components in plants |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN111956707A (en) |
TW (1) | TWI737086B (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115192620A (en) * | 2021-04-14 | 2022-10-18 | 大江生医股份有限公司 | Use of eucheuma fermentation product for preparing composition for improving metabolic state |
TWI831348B (en) * | 2021-08-31 | 2024-02-01 | 大江生醫股份有限公司 | Use of beet root fermentation for avoiding vascular calcification |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080193595A1 (en) * | 2005-09-12 | 2008-08-14 | Vrije Universiteit Brussel | Starter Cultures and Fermentation Method |
WO2017186144A1 (en) * | 2016-04-29 | 2017-11-02 | 刘东波 | Microbial fermentation of botanicals |
US20180055905A1 (en) * | 2016-08-25 | 2018-03-01 | Tci Co., Ltd. | Banana fermentation product and manufacturing method and use of the same |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104099231B (en) * | 2014-07-05 | 2016-02-17 | 南陵县葛业协会 | A kind of making method of rambutan fruit vinegar |
-
2019
- 2019-12-18 TW TW108146489A patent/TWI737086B/en active
-
2020
- 2020-01-09 CN CN202010021634.0A patent/CN111956707A/en active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080193595A1 (en) * | 2005-09-12 | 2008-08-14 | Vrije Universiteit Brussel | Starter Cultures and Fermentation Method |
WO2017186144A1 (en) * | 2016-04-29 | 2017-11-02 | 刘东波 | Microbial fermentation of botanicals |
US20180055905A1 (en) * | 2016-08-25 | 2018-03-01 | Tci Co., Ltd. | Banana fermentation product and manufacturing method and use of the same |
Also Published As
Publication number | Publication date |
---|---|
TW202108164A (en) | 2021-03-01 |
CN111956707A (en) | 2020-11-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN108553403B (en) | A kind of purposes of thermus thermophilus and saccharomycete combined fermentation product | |
TWI693899B (en) | Fermentation product of punica granatum and uses thereof | |
TWI774046B (en) | Use of solanum muricatum fermented liquid for preparing a composition for promoting skin anti-aging ability, promoting anti-glycation ability, reducing melanin content, increasing skin moisturization, reducing skin texture, reducing skin wrinkles, reducing skin redness and/or reducing fat | |
JP6322580B2 (en) | Soymilk fermented extract and hypocotyl fermented extract | |
KR101634668B1 (en) | Cosmetic composition comprising fermented extract of mistletoe for anti-oxidation or whitening | |
TWI737086B (en) | Fermentation method for increasing content of effective components in plants | |
CN110464003A (en) | A kind of anti-oxidation function food of probiotics solid state fermentation and preparation method thereof | |
TWI784229B (en) | Lonicera japonica thunb ferment, preparation method thereof and use thereof for improving skin appearance and anti-aging | |
JP2023171950A (en) | Anti-aging agent, antioxidant, anti-inflammatory agent, and whitening agent, as well as cosmetic | |
CN113842341B (en) | Roselle fermentation product and preparation method and application thereof | |
CN113876833B (en) | White mulberry fermented product and preparation method and application thereof | |
TWI809308B (en) | Use of wasabia japonica leaves for inhibiting the production of acne and reducing cutibacterium acnes secretions | |
TWI674107B (en) | Use of imperata cylindrica fermented extract for enhancing the gene expression of keratin, filaggrin and hyaluronan synthase, promoting the proliferation of collagen and elastin, and enhancing antioxidant capacity of skin cells | |
US11123386B2 (en) | Fermentation product of Punica granatum and uses thereof | |
CN110151672A (en) | A kind of lactobacillus plantarum GMNL-6 composition is used for the purposes of skin care | |
CN113855765A (en) | Glutinous rice fermented extract and anti-aging application thereof | |
TWI754345B (en) | Use of garcinia mangostana fermented liquid for preparing a composition for beautifying skin and/or reducing fat | |
TWI680772B (en) | A use of lactobacillus plantarum gmnl-6 composition for caring skin | |
JP2019182753A (en) | Endo180 production promoter | |
TWI719781B (en) | Use of herb ferment for preparing a composition for preventing obesity | |
JP7253283B2 (en) | Cosmetics and Food and Beverage Compositions | |
KR20110042993A (en) | Cosmetic compositions for preventing and improving skin aging comprising extracts from pueraria lobata ohwi's new vines | |
TW202313087A (en) | Prunus salicinaferment, manufacturing method thereof, and uses thereof | |
TW202306582A (en) | White asparagus ferment and use thereof for improving skin condition, promoting physiological metabolic activity and protecting kidney function | |
TW202402316A (en) | Uses ofprunus lannesianaextract on improving skin condition and promoting basal metabolic rate |